UBS analyst Kevin Caliendo raised the firm’s price target on Quest Diagnostics (DGX) to $190 from $180 and keeps a Neutral rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $210 from $190 at Mizuho
- Quest Diagnostics price target raised to $195 from $192 at Truist
- Quest Diagnostics price target raised to $190 from $185 at Evercore ISI
- Quest Diagnostics price target raised to $190 from $185 at Barclays
- Guardant Health, Quest Diagnostics announce blood-based screening test pact